Catalent Inc (CTLT) is Upgraded by BofA/Merrill to Buy

Catalent Inc (CTLT) was Upgraded by BofA/Merrill to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. BofA/Merrill advised their investors in a research report released on Jun 20, 2016.

Many Wall Street Analysts have commented on Catalent Inc. Catalent Inc was Downgraded by BofA/Merrill to ” Neutral” on May 5, 2016. Catalent Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Apr 21, 2016.

On the company’s financial health, Catalent Inc reported $0.20 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on May 4, 2016. Analyst had a consensus of $0.31. The company had revenue of $438.00 million for the quarter, compared to analysts expectations of $427.05 million. The company’s revenue was down -1.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.46 EPS.

Catalent Inc closed down -0.73 points or -3.29% at $21.44 with 35,06,528 shares getting traded on Friday. Post opening the session at $22.15, the shares hit an intraday low of $21.3 and an intraday high of $22.2 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Jun 1, 2016, Matthew M Walsh (officer ) sold 21,197 shares at $28.85 per share price. According to the SEC, on Aug 19, 2015, John R Chiminski (director officer ) sold 38,505 shares at $33.87 per share price. On Apr 3, 2015, Scott Houlton (officer ) sold 16,253 shares at $30.61 per share price, according to the Form-4 filing with the securities and exchange commission.

Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.

Catalent Inc

Leave a Reply

Catalent Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Catalent Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.